## Chemotherapy for Early-Stage and Non-Epithelial Ovarian Cancers **Key Point:** Even for early-stage (IB) and non-epithelial histologies (clear-cell, mucinous), paclitaxel-carboplatin remains the standard first-line adjuvant regimen, though data are less robust than for high-grade serous cancers. ### Why Paclitaxel-Carboplatin for Clear-Cell Ovarian Cancer? 1. **Evidence rationale** - Clear-cell carcinoma is a non-epithelial subtype with distinct biology (often TP53 wild-type, ARID1A mutations) - Limited prospective trials specific to clear-cell histology - Retrospective data and expert consensus support platinum-taxane doublets - Single-agent platinum (carboplatin) alone is inferior 2. **Clinical context for stage IB** - Stage IB = tumor limited to one ovary, with capsule rupture or positive washings - High-risk features (clear-cell, mucinous, grade 3) warrant adjuvant therapy - Standard: 6 cycles paclitaxel 175 mg/m² + carboplatin AUC 5–6 **High-Yield:** Clear-cell and mucinous ovarian cancers are chemotherapy-resistant compared to high-grade serous; they often harbor ARID1A mutations and are less platinum-sensitive. However, platinum-taxane doublets remain the best available option and are preferred over experimental regimens. ### Why NOT BEP or TIP? - **BEP (Bleomycin-Etoposide-Cisplatin):** Standard for germ-cell tumors (dysgerminoma, yolk-sac tumor), not epithelial or clear-cell carcinomas - **TIP (Paclitaxel-Ifosfamide-Cisplatin):** Salvage regimen for platinum-resistant disease; not first-line **Clinical Pearl:** Clear-cell ovarian cancers have worse prognosis and lower response rates to chemotherapy than high-grade serous; close surveillance and consideration of clinical trials are important after adjuvant therapy. [cite:NCCN Ovarian Cancer Guidelines 2023; ESMO Ovarian Cancer Consensus]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.